Reappraisal of guidelines on hypertension management;Přehodnocení doporučení pro diagnostiku a léčbu hypertenze

Vnitrni Lekarstvi

Volumn 56, Issue 2, 2010, Pages 157-161

  Špinar, Jindřich ^a   Souček, Miroslav ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Antihypertensives; Combination therapy; High risk patient; Hypertension

Indexed keywords

ANGIOTENSIN II ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; THIAZIDE DIURETIC AGENT; ANTIHYPERTENSIVE AGENT;

ARTICLE; BLOOD PRESSURE; DIABETES MELLITUS; GLYCEMIC CONTROL; HIGH RISK PATIENT; HUMAN; HYPERTENSION; PRACTICE GUIDELINE; SECONDARY PREVENTION; PATHOPHYSIOLOGY;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; HUMANS; HYPERTENSION; PRACTICE GUIDELINES AS TOPIC;

EID: 77749243465     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Mancia G, Laurent S, Agabiti-Rosei L et al. Reappraisal of European guidelines on hypertension management: a European Society of hypertension Task Force document. J Hypertens 2009; 27: 2121-2158.
2. Task Force Members 2007. Guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105-1187.
3. Widimský J. jr, Cífková R, Špinar J et al. Doporuc̊ení diagnostických a léčebných postupů arteriální hypertenze - verze 2007. Doporučení České společnosti pro hypertenzi. Cor Vasa 2008; 1: K3-23.
4. Widimský J. jr, Cífková R, Špinar J et al. Doporučení diagnostických a léčebných postupů arteriální hypertenze verze 2007. Doporučení České společnosti pro hypertenzi. Vnitř Lék 2008; 1: 101-118.
5. Widimský J. Komentář k přehodnocení evropských doporučení léčby arteriální hypertenze. Cor Vasa 2010; 52: v tisku.
6. Verdechia P, Angeli F, Cavalini C et al. The voltage of R wave in lead aVL improves risk stratification in hypertensive patients without ECG left ventricular hypertrophy. J Hypertens 2009; 27: 1697-1704.
7. Sebestedt T, Jepensen J, Hansen TW et al. Which markers of subclinical organ damage to measure in individuals with high normal blood pressure. J Hypertens 2009; 27: 1165-1171.
8. Inoue M, Maeda R, Kawakarni H. Aortic pulse walv velocity predict cardiovascular mortality in middle-aged and elederly Japanese men. Circ J 2009; 72: 549-553.
9. Sleight P, Redon J, Verdechia P et al. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan alone and in combination with Ramipril Global Endpoin Trial study. J Hypertens 2009; 27 (Suppl 4): 16.
10. Hypertension: management of hypertension in adults in primary care NCI/BHS; 2006. www.nice.org.uk/CG034.
11. Law MR, Moriis JK, Wald NU. Use of blood presure lowering drugs in the prevention of cardiovascular diseases: meta-analysis of 147 randomised trials in the content of expectation from prospective epidemiological studies. BMJ 2009; 338: 1665-1683.
12. Jamerson K, Weber MA, Bakris GL et al. Benazepril plus amlodipin or hydrochlorothiazide for hypertension in high risk patients. N Engl J Med 2008; 359: 2417-2428.
13. Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559.
14. Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regiment of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazidine as reguired. Lancet 2005; 366: 895-906.
15. Wald DS, Law M, Moris JK et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11 000 participants in 42 trials. Am J Med 2009; 122: 290-300.
16. Blood presure lowering trialist colaboration: Effect of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008; 238: 1121-1128.
17. Mann JG, Schmieder RE, Dyal L et al. Effect of telmisartan on renal outcomes: a randomised trial. Ann Intern Med 2009; 151: 1-10.
18. Peters R, Beckett N, Forrete F et al. Incident dementia and blood pressure lowering in the HYpertensiuon in Very Elderly Trial cognitive function asseoient. Lance Neurol 2008; 7: 683-689.
19. GISSI-AF investigators: Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 2009; 360: 1606-1617.
20. Nasr IA, Bouzamondo A Hulot JS et al. Prevention of atrial fibrillation onset by beta blocker treatment in heart failure: a meta analysis. Eur Heart J 2008; 29: 2669-2680.
21. Indian Polycap Study (TIPS): Effects of polypill (polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II double blind randomised trial. Lancet 2009; 373: 1765-1772.